Interleukin-1 blockade attenuates white matter inflammation and oligodendrocyte loss after progressive systemic lipopolysaccharide exposure in near-term fetal sheep.
Brain
Inflammation
Interleukin-1
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
31 Aug 2021
31 Aug 2021
Historique:
received:
02
02
2021
accepted:
11
08
2021
entrez:
1
9
2021
pubmed:
2
9
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Increased systemic and tissue levels of interleukin (IL)-1β are associated with greater risk of impaired neurodevelopment after birth. In this study, we tested the hypothesis that systemic IL-1 receptor antagonist (Ra) administration would attenuate brain inflammation and injury in near-term fetal sheep exposed to lipopolysaccharide (LPS). Chronically instrumented near-term fetal sheep at 0.85 of gestation were randomly assigned to saline infusion (control, n = 9), repeated LPS infusions (0 h = 300 ng, 24 h = 600 ng, 48 h = 1200 ng, n = 8) or repeated LPS plus IL-1Ra infusions (13 mg/kg infused over 4 h) started 1 h after each LPS infusion (n = 9). Sheep were euthanized 4 days after starting infusions for histology. LPS infusions increased circulating cytokines and were associated with electroencephalogram (EEG) suppression with transiently reduced mean arterial blood pressure, and increased carotid artery perfusion and fetal heart rate (P < 0.05 vs. control for all). In the periventricular and intragyral white matter, LPS-exposure increased IL-1β immunoreactivity, numbers of caspase 3+ cells and microglia, reduced astrocyte and olig-2+ oligodendrocyte survival but did not change numbers of mature CC1+ oligodendrocytes, myelin expression or numbers of neurons in the cortex and subcortical regions. IL-1Ra infusions reduced circulating cytokines and improved recovery of EEG activity and carotid artery perfusion. Histologically, IL-1Ra reduced microgliosis, IL-1β expression and caspase-3+ cells, and improved olig-2+ oligodendrocyte survival. IL-1Ra improved EEG activity and markedly attenuated systemic inflammation, microgliosis and oligodendrocyte loss following LPS exposure in near-term fetal sheep. Further studies examining the long-term effects on brain maturation are now needed.
Sections du résumé
BACKGROUND
BACKGROUND
Increased systemic and tissue levels of interleukin (IL)-1β are associated with greater risk of impaired neurodevelopment after birth. In this study, we tested the hypothesis that systemic IL-1 receptor antagonist (Ra) administration would attenuate brain inflammation and injury in near-term fetal sheep exposed to lipopolysaccharide (LPS).
METHODS
METHODS
Chronically instrumented near-term fetal sheep at 0.85 of gestation were randomly assigned to saline infusion (control, n = 9), repeated LPS infusions (0 h = 300 ng, 24 h = 600 ng, 48 h = 1200 ng, n = 8) or repeated LPS plus IL-1Ra infusions (13 mg/kg infused over 4 h) started 1 h after each LPS infusion (n = 9). Sheep were euthanized 4 days after starting infusions for histology.
RESULTS
RESULTS
LPS infusions increased circulating cytokines and were associated with electroencephalogram (EEG) suppression with transiently reduced mean arterial blood pressure, and increased carotid artery perfusion and fetal heart rate (P < 0.05 vs. control for all). In the periventricular and intragyral white matter, LPS-exposure increased IL-1β immunoreactivity, numbers of caspase 3+ cells and microglia, reduced astrocyte and olig-2+ oligodendrocyte survival but did not change numbers of mature CC1+ oligodendrocytes, myelin expression or numbers of neurons in the cortex and subcortical regions. IL-1Ra infusions reduced circulating cytokines and improved recovery of EEG activity and carotid artery perfusion. Histologically, IL-1Ra reduced microgliosis, IL-1β expression and caspase-3+ cells, and improved olig-2+ oligodendrocyte survival.
CONCLUSION
CONCLUSIONS
IL-1Ra improved EEG activity and markedly attenuated systemic inflammation, microgliosis and oligodendrocyte loss following LPS exposure in near-term fetal sheep. Further studies examining the long-term effects on brain maturation are now needed.
Identifiants
pubmed: 34465372
doi: 10.1186/s12974-021-02238-4
pii: 10.1186/s12974-021-02238-4
pmc: PMC8408978
doi:
Substances chimiques
Interleukin 1 Receptor Antagonist Protein
0
Lipopolysaccharides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
189Subventions
Organisme : National Health and Medical Research Council
ID : 1090890
Organisme : National Health and Medical Research Council
ID : 1164954
Organisme : Health Research Council of New Zealand
ID : 17/601
Informations de copyright
© 2021. The Author(s).
Références
Resuscitation. 2014 Apr;85(4):567-72
pubmed: 24361672
Brain Behav Immun. 2013 Mar;29:104-112
pubmed: 23295265
J Cereb Blood Flow Metab. 2017 Apr;37(4):1362-1373
pubmed: 27317658
Dev Neurosci. 2014;36(2):73-82
pubmed: 24854050
Neuroimmunomodulation. 2010;17(6):405-10
pubmed: 20516722
Lancet Glob Health. 2018 Mar;6(3):e248-e249
pubmed: 29433660
Pediatr Res. 2020 Jul;88(1):27-37
pubmed: 32120374
Arch Dis Child. 2021 Jan 22;:
pubmed: 33483376
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S173-S189
pubmed: 29117330
J Neuroinflammation. 2015 Jun 06;12:114
pubmed: 26048578
J Physiol. 2013 Apr 15;591(8):2127-37
pubmed: 23420658
MMWR Morb Mortal Wkly Rep. 2004 Jan 30;53(3):57-9
pubmed: 14749614
Pediatr Res. 2002 Dec;52(6):892-9
pubmed: 12438667
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14384-9
pubmed: 23946428
Neurosci Lett. 2004 Sep 30;368(3):332-6
pubmed: 15364422
Lymphokine Cytokine Res. 1993 Aug;12(4):231-6
pubmed: 7692988
PLoS One. 2013;8(3):e59327
pubmed: 23527164
J Cereb Blood Flow Metab. 1997 Dec;17(12):1337-45
pubmed: 9397033
Brain Dev. 2006 Apr;28(3):178-82
pubmed: 16181755
J Rheumatol Suppl. 2002 Sep;65:16-21
pubmed: 12236617
Neural Regen Res. 2018 Feb;13(2):181-189
pubmed: 29557357
J Steroid Biochem Mol Biol. 2016 Jun;160:181-8
pubmed: 26365557
Semin Arthritis Rheum. 2007 Dec;37(3):189-97
pubmed: 17583775
J Immunol. 2007 Dec 15;179(12):8491-9
pubmed: 18056396
Brain Behav Immun. 2003 Jun;17(3):152-7
pubmed: 12706413
Ann Neurol. 2003 May;53(5):588-95
pubmed: 12730992
Biol Chem. 1999 Feb;380(2):259-64
pubmed: 10195433
J Neurosci. 2001 Feb 15;21(4):1302-12
pubmed: 11160401
Ann Neurosci. 2017 Jul;24(3):146-154
pubmed: 28867896
J Neuroinflammation. 2014 May 16;11:89
pubmed: 24886663
Innate Immun. 2009 Apr;15(2):101-7
pubmed: 19318420
Brain Behav Immun. 2021 May;94:338-356
pubmed: 33307171
Dev Med Child Neurol. 2015 Apr;57 Suppl 3:48-50
pubmed: 25800493
J Comp Neurol. 1969 Mar;135(3):249-62
pubmed: 4306038
Am J Physiol Regul Integr Comp Physiol. 2014 Aug 15;307(4):R387-95
pubmed: 24944248
PLoS One. 2019 Nov 19;14(11):e0225328
pubmed: 31743377
Cytokine. 2008 Jul;43(1):54-62
pubmed: 18511291
JAMA. 2003 Nov 26;290(20):2677-84
pubmed: 14645309
Immunology. 2014 Mar;141(3):302-13
pubmed: 23981039
Immunol Rev. 2018 Jan;281(1):8-27
pubmed: 29247995
PLoS One. 2010 Dec 22;5(12):e15328
pubmed: 21203525
Arch Dis Child Fetal Neonatal Ed. 2016 Mar;101(2):F137-42
pubmed: 26265677
Front Neurol. 2018 Jan 23;9:8
pubmed: 29410649
J Cereb Blood Flow Metab. 2015 Sep;35(9):1388-95
pubmed: 26082012
J Physiol. 2016 Mar 1;594(5):1281-93
pubmed: 26077461
Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R760-6
pubmed: 20071615
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
J Child Neurol. 2005 Dec;20(12):960-4
pubmed: 16417842
Int J Mol Sci. 2020 Nov 24;21(23):
pubmed: 33255257
J Neuropathol Exp Neurol. 2010 Nov;69(11):1116-29
pubmed: 20940629
Dev Med Child Neurol. 2018 Jun;60(6):543-558
pubmed: 29319155
Front Neurol. 2020 May 27;11:449
pubmed: 32536903
J Neuroinflammation. 2020 Mar 23;17(1):92
pubmed: 32293473
Dev Neurosci. 2015;37(4-5):390-7
pubmed: 26087775
JAMA. 1997 Jul 16;278(3):207-11
pubmed: 9218666
Brain. 2020 Feb 1;143(2):467-479
pubmed: 31942938
Ann Neurol. 2011 Oct;70(4):550-65
pubmed: 21796662
Am J Physiol Regul Integr Comp Physiol. 2009 Mar;296(3):R640-50
pubmed: 19109376
Ann Neurol. 1997 Sep;42(3):335-48
pubmed: 9307255
Pediatr Res. 2002 Mar;51(3):310-6
pubmed: 11861935
Stroke. 2003 Sep;34(9):2240-5
pubmed: 12933964
J Neuroinflammation. 2017 Dec 12;14(1):244
pubmed: 29233180
Lancet. 1998 Oct 17;352(9136):1271-7
pubmed: 9788457
Pediatr Res. 2009 Jan;65(1):85-9
pubmed: 18787422
J Pediatr. 2012 Mar;160(3):395-401.e4
pubmed: 22000304
Am J Respir Crit Care Med. 2009 May 15;179(10):955-61
pubmed: 19234101
PLoS One. 2012;7(6):e39273
pubmed: 22720088
J Cereb Blood Flow Metab. 2011 Feb;31(2):439-47
pubmed: 20628399
Ann Neurol. 2011 May;69(5):743-58
pubmed: 21520238
J Neuroimmunol. 1994 Feb;50(1):17-24
pubmed: 8300853
Brain Res Dev Brain Res. 2003 Feb 16;140(2):205-14
pubmed: 12586426
Pediatr Res. 2021 Feb;89(3):464-475
pubmed: 32521540
Pediatr Res. 2004 Dec;56(6):960-6
pubmed: 15496611
Dev Neurosci. 2017;39(1-4):7-22
pubmed: 27988510
Trends Cell Biol. 2004 Apr;14(4):184-93
pubmed: 15066636
Am J Reprod Immunol. 2014 May;71(5):418-26
pubmed: 24592965
Brain Behav Immun. 2012 Nov;26(8):1331-9
pubmed: 22982341
J Neuroimmunol. 2010 Jun;223(1-2):138-40
pubmed: 20421138
Neonatology. 2018;113(3):212-220
pubmed: 29275405
J Neuroinflammation. 2017 Mar 3;14(1):44
pubmed: 28253907